On the contrary, older patients have been shown to have lower progression-free survival (PFS) and overall survival (OS) rates than younger patients in the CheckMate-017 trial for NSCLC, CheckMate-025 trial for RCC, Keynote-045 and 052 trials for urothelial carcinoma (as monotherapy), CheckMate-067 trial for melanoma, CheckMate-214 trial for RCC, and CheckMate-227 trial for NSCLC (which involved anti-PD-1/PD-L1-based combination therapies). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.